Reply
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In REDUCE-IT, benefits of icosapent ethyl on total ischemic events were consistent across baseline and achieved triglyceride levels.
“Analysis of total ischemic events (first and subsequent events) found a significant 30% reduction, with consistent benefits across baseline and achieved triglyceride levels.5–9”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [7]
Analysis of total ischemic events in REDUCE-IT found a significant 30% reduction.
“Analysis of total ischemic events (first and subsequent events) found a significant 30% reduction, with consistent benefits across baseline and achieved triglyceride levels.5–9”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [7]
REDUCE-IT found a significant 25% relative risk reduction in first ischemic events with icosapent ethyl 4 g/d versus placebo in statin-treated patients with triglycerides >~135 mg/dL.
“REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) addressed this residual risk, finding a significant 25% relative risk reduction in first ischemic events with icosapent ethyl 4 g/d versus placebo in statin-treated patients with triglycerides >~135 mg/dL.4–7”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · see citing works
Self-citationEffects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.032 · Cited by 259 · see citing works
Self-citationUnmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195 · see citing works
Self-citationBhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Jiao, L., Tardif, J.-C., Gregson, J., Pocock, S. J., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.043 · Cited by 97 · see citing works
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1902165 · Cited by 24 · see citing works
WHAT MADE MY HEART STOP? A RARE CAUSE OF SUDDEN CARDIAC ARREST
Hussain, M. A., Nabi, F., Awar, M., & Valderrábano, M. (2019) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(19)33397-2 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407 · see citing works
Self-citationREDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136 · see citing works
Self-citationGaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.035 · Cited by 61 · see citing works
Self-citation
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Juliano, R. A., & Ballantyne, C. M.
- Corresponding author
- Bhatt, Deepak L.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 74
- Issue
- 14
- Pages
- 1849-1850
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2978852271
- Cited by
- 11
- References
- 6
- Citations by year
- 2022: 4 · 2021: 2 · 2020: 4 · 2019: 1
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- REDUCE-IT trial, icosapent ethyl, triglyceride-rich lipoproteins, apolipoproteins, cardiovascular events
- MeSH terms
- Brain Ischemia, Humans, Ischemia, Triglycerides, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
